RECOMBINANT TRIVALENT VACCINE AGAINST HUMAN INFLUENZA

摘要

The invention relates to medicine, in particular to prevention of infectious diseases of the respiratory tract in humans, including influenza virus by vaccines. Recombinant trivalent vaccine against human influenza contains recombinant adenoviral vector with a nucleotide sequence which encodes at least one antigen of influenza virus strain, while non-replicating nanoparticles are used as adenoviral vectors based on genome of human adenovirus of serotype 5, capable of expressing the haemagglutinin of influenza virus which induce human immune response to influenza virus, wherein the vaccine contains composition of three kinds of non-replicating nanoparticles, each of which carries different influenza hemagglutinin genes, further comprises immunostimulant and formulating buffer. In this solution the influenza virus hemagglutinin genes are: H1, H3, HB and any other recommended by the World Health Organization at the time of production. Formulating buffer is added to the composition to achieve a total volume of 0.5 ml and a vaccine dose of 0.5 ml. Recombinant trivalent vaccine contains:
- Non-replicating nanoparticles with inset of hemagglutinin H1 not more than 10 7 PFU;
- Non-replicating nanoparticles with inset of hemagglutinin H3 not more than 10 7 PFU;
- Non-replicating nanoparticles with inset of hemagglutinin HB not more than 10 7 PFU;
- Immunostimulant 1 - 20 µg Peptidoglycans are used as immunostimulants, and acidic peptidoglycan having a molecular weight of from 1,200 to 40,000 kDa is used as peptidoglycan. In another embodiment, peptidoglycan of bacteria cell wall is used as a peptidoglycan. Recombinant trivalent vaccine is administered intranasally.